Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
Open Access
- 1 September 2007
- journal article
- research article
- Published by SAGE Publications in Diabetes and Vascular Disease Research
- Vol. 4 (3), 214-221
- https://doi.org/10.3132/dvdr.2007.042
Abstract
This randomised, double-blind, parallel-group study assessed the effects of addition of the dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, tesaglitazar, for 24 weeks to the therapeutic regimen of 392 poorly controlled (glycosylated haemoglobin [HbA1C] 7.5-10%) insulin-treated, type 2 diabetes patients. At 24 weeks, tesaglitazar 0.5 mg resulted in a 0.66% (95% confidence intervals: −0.85, −0.47; p<0.0001) reduction from baseline in HbA1C, and reduced fasting plasma glucose (p<0.0001) and daily insulin dose (p=0.014) versus placebo. After 24 weeks, tesaglitazar caused greater improvements from baseline in triglyc-erides (p<0.0001), high-density lipoprotein cholesterol (HDL-C) (p<0.001), non-HDL-C (p<0.05), apolipopro-tein (apo)A-I (p<0.05) and apoB levels (p<0.01) than placebo. Tesaglitazar was generally well tolerated but was associated with a greater increase in serum creatinine level than placebo. The clinical development of tesaglitazar is no longer continuing; its effects on the glucose and lipid abnormalities of type 2 diabetes suggest that the concept of dual PPARα/γ agonism is worthy of further investigation.Keywords
This publication has 27 references indexed in Scilit:
- The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetesDiabetes and Vascular Disease Research, 2007
- A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitusDiabetes and Vascular Disease Research, 2007
- Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetesDiabetes and Vascular Disease Research, 2007
- Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and WomenJournal of the American College of Cardiology, 2007
- Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trialCurrent Medical Research and Opinion, 2006
- The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed DyslipidemiaJournal of the American College of Cardiology, 2006
- Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Peroxisome Proliferator-Activated Receptors and AtherogenesisCirculation Research, 2004
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Troglitazone Use in Insulin-Treated Type 2 Diabetic PatientsDiabetes Care, 1998